NNVC : Summary for NanoViricides, Inc. NEW Common - Yahoo Finance

U.S. Markets closed

NanoViricides, Inc. (NNVC)


NYSE MKT - NYSE MKT Delayed Price. Currency in USD
Add to watchlist
1.14+0.01 (+0.88%)
At close: 4:01PM EST
People also watch
BTXISCOGALTECTEAVXL
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Previous Close1.13
Open1.11
Bid0.00 x
Ask0.00 x
Day's Range1.11 - 1.15
52 Week Range1.03 - 3.44
Volume80,597
Avg. Volume108,791
Market Cap66.35M
Beta0.06
PE Ratio (TTM)-5.18
EPS (TTM)N/A
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • PR Newswire7 days ago

    NanoViricides Files Quarterly Report for Period Ending 2016-12-31

    SHELTON, Conn., Feb. 16, 2017 /PRNewswire/ -- NanoViricides, Inc. (NYSE MKT: NNVC) (the "Company"), filed its quarterly report for its second quarter of financial year 2017 in a timely manner with the Securities and Exchange Commission on Tuesday, February 14th. NanoViricides reported that it had approximately $19.44 Million (M) of current assets (cash, cash equivalents, and prepaid expenses) as of December 31, 2016, the end of the reporting period. The net cash used in operating activities during this quarter was approximately $2.6 M. The Company's research and development (R&D) expenditure has increased as we advance towards human clinical trials.

  • Associated Press8 days ago

    NanoViricides reports 2Q loss

    On a per-share basis, the Shelton, Connecticut-based company said it had a loss of 3 cents. Losses, adjusted for non-recurring gains, were 4 cents per share. The company's shares closed at $1.17. A year ...

  • PR Newswire10 days ago

    NanoViricides Reports the Company's Director Dr. Boniuk Converted Series B Debenture to Equity Effectively Raising $5M in New Equity for the Company

    SHELTON, Conn., Feb. 13, 2017 /PRNewswire/ -- NanoViricides, Inc. (NYSE MKT: NNVC), a global leader in the development of highly effective antiviral therapies based on a novel nanomedicines platform (the "Company"), reports today that a substantial portion of its Series B Convertible Debentures, with a maturity date of January 31, 2017, have been converted into restricted common stock, effectively retaining $5 million in cash for the Company. The Company offered a conversion proposal to all holders of the Series B Convertible Debentures, with a total principal value of $6,000,000. An entity controlled by Dr. Boniuk and the Boniuk Charitable Foundation accepted the Company's offer to convert debentures in the aggregate principal amount of $5,000,000.